Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Greipp

Showing results (151-160 of 178) with videos related to

Pageof 18
Sort By:
Blood|April 6, 2001
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and deathD P Steensma, M A Gertz, P R Greipp, et al.
Leukemia|January 30, 2004
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaS Kumar, T E Witzig, A Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Prognostic value of bone marrow angiogenesis in multiple myelomaS V Rajkumar, T Leong, P C Roche, et al.
Bone Marrow Transplantation|June 1, 2004
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapyS Kumar, M A Gertz, A Dispenzieri, et al.
Leukemia|January 15, 2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisP Kapoor, S V Rajkumar, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Leukemia|July 4, 2008
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemC L H Snozek, J A Katzmann, R A Kyle, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia & Lymphoma|December 28, 1999
Clinical significance of the translocation (11;14)(q13;q32) in multiple myelomaR Fonseca, J D Hoyer, P Aguayo, et al.
Pageof 18

Showing results (151-160 of 178) with videos related to

Sort By:
Pageof 18
Blood|April 6, 2001
A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and deathD P Steensma, M A Gertz, P R Greipp, et al.
Leukemia|January 30, 2004
Effect of thalidomide therapy on bone marrow angiogenesis in multiple myelomaS Kumar, T E Witzig, A Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2000
Prognostic value of bone marrow angiogenesis in multiple myelomaS V Rajkumar, T Leong, P C Roche, et al.
Bone Marrow Transplantation|June 1, 2004
Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapyS Kumar, M A Gertz, A Dispenzieri, et al.
Leukemia|January 15, 2011
Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysisP Kapoor, S V Rajkumar, A Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2001
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survivalA Dispenzieri, M Q Lacy, R A Kyle, et al.
Leukemia|April 7, 2011
Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myelomaP Kapoor, S Kumar, S J Mandrekar, et al.
Leukemia|July 4, 2008
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemC L H Snozek, J A Katzmann, R A Kyle, et al.
Leukemia|April 12, 2003
Thalidomide as initial therapy for early-stage myelomaS V Rajkumar, M A Gertz, M Q Lacy, et al.
Leukemia & Lymphoma|December 28, 1999
Clinical significance of the translocation (11;14)(q13;q32) in multiple myelomaR Fonseca, J D Hoyer, P Aguayo, et al.
Pageof 18